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Sumit	Jamuar:	Indians	are	20%	of	the	world’s
population,	but	represent	only	1%	of	existing	genetic
data
As	the	new	frontier	in	medicine,	genomics	brings	with	it	the	hope	of	allowing	researchers	to	find	the	cure	for	a
number	of	largely	incurable	diseases,	from	cancer	to	Alzheimer’s,	to	infectious	diseases	and	beyond.	The	challenge
now	is	to	map	the	DNA	of	as	many	ethnicities	and	nationalities	as	possible.		Currently,	81	per	cent	of	the	existing
genetic	data	is	from	Caucasians.	One	company	is	trying	to	bridge	the	gap	by	analysing	the	genome	of	different
ethnicities	in	India,	with	hopes	of	expanding	to	the	rest	of	Asia,	Latin	America	and	Africa.	“You	look	at	India,	with	1.3
billion	people,	20	per	cent	of	the	world’s	population.	A	lot	of	people	of	Indian	ethnicities	reside	globally,	and	yet	they
comprise	less	than	1	per	cent	of	genomic	insights	and	understanding”,	says	Sumit	Jamuar,	chairman	and	CEO	of
Global	Gene	Corp.	He	spoke	with	LSE	Business	Review’s	managing	editor,	Helena	Vieira,	on	9	November	2017,
during	Web	Summit	in	Lisbon.
What	exactly	does	Global	Genecorp	do?
One	of	the	biggest	problems	you	have	in	genomics	is	that	a	large	percentage	of	the	world’s	population	is	not	well
understood	genetically.	Currently,	81	per	cent	of	the	existing	genetic	data	is	from	Caucasians.	From	studies,	we
know	that	different	populations	exhibit	different	traits.	Consequently	you	need	the	underlying	insights	and	data	–	the
data	foundation	–	to	be	able	to	use	this	technology.	Science	is	all	about	data.	The	right	data	give	you	the	insights.
That’s	what	we’re	creating.
To	give	you	a	sense	of	the	numbers,	I	estimate	that	60	per	cent	of	the	world’s	population	represent	less	than	5	per
cent	of	genomic	data.	You	look	at	India,	with	1.3	billion	people,	20	per	cent	of	the	world’s	population.	A	lot	of	people
of	Indian	ethnicities	reside	globally,	and	yet	they	comprise	less	than	1	per	cent	of	genomic	insights	and
understanding.
We’re	very	excited	by	genomics	as	a	technology,	because	it’s	one	of	the	truly	disruptive	technologies	with	the
potential	to	affect	each	one	of	us	as	an	individual.	We’re	fascinated	by	the	possibility	that	not	only	can	you	treat
disease,	but	also	keep	people	healthier	for	longer.	Given	that	we’re	at	Web	Summit,	think	about	DNA	as	a	computer
code.	The	code	gives	us	a	sense	of	who	human	beings	are,	with	the	operating	instructions	included.	It	allows	us	to
see	the	risks	over	our	lifetime	and	understand	what	we	need	to	do	in	order	to	mitigate	and	manage	those	risks.	If
something	happens,	we	know	what	the	right	course	of	treatment	is.	That	is	truly	the	possibility	of	genomics	and
precision	medicine.
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So	you’re	going	to	be	focussing	on	India?
Our	focus	is	Asia,	Latin	America	and	Africa,	which	is	a	very	large	scope.	Where	did	we	start?	We	started	in	India,
because	in	the	beginning	you	need	to	set	up	and	operate	new	systems.	Given	the	large	contribution	that	India	has,
from	a	population	perspective,	with	5,000	ethnicities	and	special	characteristics	in	terms	of	family	structures	and
other	elements,	it	gives	us	a	tremendous	opportunity	to	create	greater	understanding.	India	in	some	ways	was	the
last	frontier	of	genomics.	Building	from	that,	we’ll	expand	in	the	rest	of	Asia,	Latin	America	and	Africa.	Our
fundamental	aim	is,	‘how	do	we	solve	the	data	problem?”	That	goes	back	to	our	objective	of	democratising
healthcare	through	genomics.
What	is	the	product	that	you’re	selling?
At	the	current	moment	we’re	looking	at	collaborations	and	partnerships	with	other	esteemed	parties,	which	could	be
governments,	research	institutions,	pharmas	or	biotechs,	to	enhance	the	understanding,	create	the	genomic
understanding	about	individuals	and	the	insights.	We’re	working	towards	that.	Let’s	create	the	data	foundation,	and
start	generating	insights.	Of	course	you	can	apply	a	lot	of	artificial	intelligence	and	machine	learning	to	create
algorithms	as	well	as	products	that	are	relevant	to	help	the	individual	stay	healthy	and	look	at	the	propensity,	cause-
effect,	and	what	can	be	done	to	manage	certain	conditions.
We	have	to	look	at	the	different	phases.	As	an	industry	we’re	still	at	an	early	stage.	The	first	human	genome	project
was	done	in	2003.	It	took	13	years	and	$	2.7	billion.	Now,	14	years	later,	sequencing	DNA	takes	about	$1,000	and
just	a	few	hours.	That’s	the	transformation	of	technology.	We’re	2.7	million	times	cheaper,	and	much	faster.	Over	the
past	30	years,	artificial	intelligence	has	improved	its	capability	1	million	times.	We	expect	that	in	the	next	30	years
you	will	see	it	a	million	times	improved.	These	are	logarithmic	movements,	not	arithmetic	movements.	We’re	looking
at	significant	improvement	in	performance.
As	the	technology	improves,	it	just	keeps	building	up.	But	what	you	need	to	have	is	the	first	phase	of	the	foundation
in	order	to	be	able	to	build	the	next	phase	of	things.	I	always	liken	it	to	the	same	stage	where	the	internet	was	in
1995,	when	Amazon	was	just	starting	out,	Google	wasn’t	yet	created,	the	iPhone	didn’t	exist.	Now,	20	plus	years
since,	we	have	this	thing	where	smart	phones	are	indispensable.	Our	behaviour	has	changed	significantly.	And	that’s
the	sort	of	generational	shift	that	we	expect.
So	you’re	not	profitable	yet…
No,	at	this	point,	such	an	early	stage,	it’s	like	building	a	dam.	Once	you	build	it,	electricity	costs	you	nothing	to
generate,	but	to	build	a	dam	takes	a	substantial	amount	of	investment	to	make	it	happen.
Who	do	you	foresee	would	be	your	clients,	using	what	you’re	building?
One	use	case	is	pharmaceuticals.	They’re	facing	a	huge	challenge	in	terms	of	their	pipeline,	huge	pressures	in	terms
of	the	patent	cliffs.	Over	90	per	cent	of	pharmaceutical	drugs	that	go	into	trial	fail.	That’s	their	reality.	When	you	look
at	application	genomics	and	biomarkers,	you	find	that	the	success	rate	triples.	That’s	the	data.	Think	about	a	drug
development	process	in	which	$1,5	to	$2	billion	are	invested.	You	want	to	generate	insights	that	allow	you	to
accelerate	drug	development.	You	fail	faster,	but	also	succeed	faster.	Let’s	try	to	link	that	to	what	happens	in
genomics.
If	you	look	at	the	global	perspective,	you	find	certain	isolated	populations	that	give	you	understanding,	because	they
should	have	some	special	characteristics	that	allow	you	to	find	your	next	blockbuster.	I’ll	give	you	an	example.
There’s	a	gene	called	PCSK9	that	was	found	in	a	particular	population	with	low	cholesterol	levels.	That
understanding	and	insight	about	the	mechanism	that	led	to	lower	cholesterol	allowed	the	creation	of	blockbuster
cholesterol	drugs	with	global	applications.	While	this	was	found	in	one	small	population,	it	was	applied	globally.
There	are	similar	things	with	promising	results.	In	Canada,	in	a	homogeneous	population,	there’s	a	gene	called
SCN9A.	People	with	that	gene	do	not	feel	pain.	That	is	being	used	to	develop	analgesics	and	other	things,	which	is
really	exciting.	If	you	look	at	pharma	now,	there	are	enough	studies	being	done	by	the	FDA	and	others.	In	most
cases,	drugs	aren’t	effective.	If	you	look	at	cancer,	unfortunately,	3	out	of	4	oncology	drugs	developed	are	ineffective.
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So	if	you	move	from	the	drug	development	side,	there	could	be	drugs	on	the	market	right	now	where	they	figured	out
that	Helena	has	a	higher	propensity	to	respond	to	that	drug	than	Sumit,	or	vice	versa.	There’s	a	classic	case	of	small
cell	lung	cancer.	You	look	at	something	like	EGFR	mutation.	If	you	have	this	mutation,	the	drug	is	15	times	more
effective	than	if	you	don’t.	You	have	a	76	per	cent	chance	of	a	positive	response.	If	you	don’t	have	that	mutation,	you
have	a	single	digit	chance	of	a	positive	response	(about	5	per	cent).	Its	predominance	is	more	on	the	East	Asian
population.	So	suddenly	you	have	this	opportunity	to	collect	data	that	could	lead	to	the	development	of	new	drugs.
Regulators	are	rightly	asking,	“show	me	real	world	evidence,	show	me	that	this	works”.	If	you’re	able	to	work
collaboratively	with	partners	to	demonstrate	real	world	evidence,	that	is	absolutely	phenomenal.	What	we’re
passionate	about	is	producing	positive	consequences	for	any	individual.	That’s	what	the	promise	of	precision
medicine	is.
Sometimes	with	start-ups,	once	they	grow,	their	mission	becomes	secondary	to	the	profit	motive.	Are	you
building	anything	in	your	project	that	will	make	sure	that	this	will	really	benefit	the	majority	of	the
population?
The	most	important	thing	in	my	mind	is	why	we	set	this	up.	I	am	exceptionally	privileged	and	fortunate	to	have
achieved	what	I	have.	The	kinds	of	people	that	I	have	connections	with,	whether	it’s	Jonathan,	Kushagra	or	Saumya,
who	are	the	co-founders,	or	the	folks	that	we	have	in	our	team,	whether	it’s	Yaron,	or	Shalendra	or	others,	we’re
blessed	with	that	network.
As	a	company,	the	most	important	thing	is	to	say,	“What	is	the	philosophy?	Why	are	we	doing	what	we’re	doing?
What’s	our	mission?”	And	it’s	very	important	to	have	that	mission	right	and	centre,	at	the	heart	of	it.	You	start	out	with
the	mission,	then	you	create	the	right	business	model.	We	actually	tell	people,	“If	you	don’t	believe	in	this	mission,	if
you’re	coming	for	other	reasons,	don’t	join	us.	It’s	going	to	be	fun,	but	you	may	not	enjoy	it,	because	it’s	a	journey.
And	you	have	to	believe	in	those	values.”
Then	you	put	the	right	business	model	in	place.	Everything	else	is	a	consequence,	because	if	you’re	addressing	a
real	customer	need,	everything	else	takes	care	of	itself.	My	family	and	my	co-founders	and	the	company,	because
it’s	really	important,	will	continue	that	dialogue.	As	we	grow,	we	have	a	mission	for	what	we	use	the	resources	we
create	for.	Our	view	is	to	create	a	science	company	to	do	exceptional	science.	The	scientists	and	the	clinicians	have
to	get	on	with	doing	this.	My	role	is	to	make	sure	that	that	core	happens	and	it	remains,	and	that’s	why	we	do	what
we	do.
One	of	the	most	profitable	business	models	today	is	to	collect	private	consumer	data,	package	it	and	sell	it,
often	times	without	the	consumer	knowing	that	information	is	being	collected.	Is	that	going	to	be	part	of
your	model?
It’s	too	early	to	tell	what	our	evolution	will	look	like.	Maybe	when	we	have	a	conversation	in	the	future,	I	will	be	in	a
much	better	position	to	reply.	What	we’re	very	clear	on	is	that	it’s	important	to	be	very	consistent,	and	not	only	follow
ethical	standards	and	guidelines,	but	make	sure	that	you’re	a	part	of	it.	That’s	a	core	principle	of	the	business.	When
we’re	closer	to	the	bridge	those	values	will	allow	us	to	respond	to	that	situation	and	we’ll	have	a	much	more	real
conversation	in	the	future.
One	last	question	regarding	the	subject	of	your	talk	here,	do	you	expect	humans	to	live	to	be	125	any	time
soon?
I	don’t	know	about	me,	but	I	would	definitely	say	that	about	future	generations.	Some	very	promising	insights	are
being	created	around	the	science.	There	are	also	clusters	such	as	Okinawa	and	Sardinia,	where	people	live	a	long
and	healthy	life.	The	key	objective	for	me	would	be:	it’s	not	about	longevity,	personally	and	necessarily,	but	it’s	also
about	the	quality	of	life.	What	I	would	definitely	like,	personally,	is	to	reduce	the	length,	between	morbidity	and
mortality.	So	I	would	say	in	the	next	couple	of	generations	we’ll	definitely	see	that	happening	more	and	more.
Already	if	you	look	at	Japan,	there	are	about	65	thousand	people	who	are	above	the	age	of	100.	That’s	a
phenomenal	number.	So,	we	have	societies	that	we	can	learn	from.	Genetic	insights	will	be	coming	and	will	be
translated,	and	then	in	the	future	you	will	likely	have	things	like	gene	editing.	So,	I	would	expect	that	in	a	couple	of
generations	people	will	have	healthier,	longer	lives.
♣♣♣
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This	Q&A	is	the	last	one	in	a	series	of	11	interviews	during	the	Web	Summit	conference	in	Lisbon,	6-
9	November	2017.	The	conversation	was	edited	for	clarity	and	brevity.	
The	post	gives	the	views	of	the	interviewee,	not	the	position	of	LSE	Business	Review	or	of	the	London	School
of	Economics	and	Political	Science.
Featured	image	credit:	Courtesy	of	GA4GH.	Not	under	a	Creative	Commons	licence.	All	rights	reserved.
When	you	leave	a	comment,	you’re	agreeing	to	our	Comment	Policy.
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